Literature DB >> 16147436

Methods and potentials of magnetic resonance imaging for monitoring radiofrequency hyperthermia in a hybrid system.

J Gellermann1, W Wlodarczyk, A Feussner, H Fähling, J Nadobny, B Hildebrandt, R Felix, P Wust.   

Abstract

INTRODUCTION: Non-invasive thermometry (NIT) is a valuable and probably indispensable tool for further development of radiofrequency (RF) hyperthermia. A hybridization of an MRI scanner with a hyperthermia system is necessary for a real-time NIT. The selection of the best thermographic method is difficult, because many parameters and attributes have to be considered.
METHODS: In the hybrid system (Siemens Symphony/BSD-2000-3D) the standard methods for NIT were tested such as T1, diffusion (ADC: apparent diffusion coefficient) and proton-resonance-frequency shift (PFS) method. A series of three-dimensional datasets was acquired with different gradient-echo sequences, diffusion-weighted EPI spin-echo sequences and calculated MR-temperatures in the software platform AMIRA-HyperPlan. In particular for the PFS-method, corrective methods were developed and tested with respect to drift and other disturbances. Experiments were performed in phantoms and the results compared with direct temperature measurements. Then the procedures were transferred to clinical applications in patients with larger tumours of the lower extremity or the pelvis.
RESULTS: Heating experiments and MR-thermography in a homogeneous cylindrical phantom give an excellent survey over the potentials of the methods. Under clinical conditions all these methods have difficulties due to motion, physiological changes, inhomogeneous composition and susceptibility variations in human tissues. The PFS-method is most stable in patients yielding reasonable MR temperature distributions and time curves for pelvic and lower extremity tumours over realistic treatment times of 60-90 min. Pooled data exist for rectal tumour recurrencies and soft tissue sarcomas. The fat tissue can be used for drift correction in these patients. T1 and diffusion-dependent methods appear less suitable for these patients. The standard methods have different sensitivities with respect to the various error sources. The advantages and pitfalls of every method are discussed with respect to the literature and illustrated by the phantom and patient measurements.
CONCLUSIONS: MR-controlled RF hyperthermia in a hybrid system is well established in phantoms and already feasible for patients in the pelvic and lower extremity region. Under optimal conditions the temperature accuracy might be in the range of 0.5 degrees C. However a variety of developments, especially sequences and post-processing modules, are still required for the clinical routine.

Entities:  

Mesh:

Year:  2005        PMID: 16147436     DOI: 10.1080/02656730500070102

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  32 in total

1.  Quality assurance for clinical studies in regional deep hyperthermia.

Authors:  Gregor Bruggmoser; Stefan Bauchowitz; Richard Canters; Hans Crezee; Michael Ehmann; Johanna Gellermann; Ulf Lamprecht; Nicoletta Lomax; Marc Benjamin Messmer; Oliver Ott; Sultan Abdel-Rahman; Rolf Sauer; Manfred Schmidt; Andreas Thomsen; Rüdiger Wessalowski; Gerard van Rhoon
Journal:  Strahlenther Onkol       Date:  2011-09-19       Impact factor: 3.621

Review 2.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

3.  Improved hyperthermia treatment control using SAR/temperature simulation and PRFS magnetic resonance thermal imaging.

Authors:  Zhen Li; Martin Vogel; Paolo F Maccarini; Vadim Stakhursky; Brian J Soher; Oana I Craciunescu; Shiva Das; Omar A Arabe; Williams T Joines; Paul R Stauffer
Journal:  Int J Hyperthermia       Date:  2010-11-11       Impact factor: 3.914

Review 4.  MR thermometry for monitoring tumor ablation.

Authors:  Baudouin Denis de Senneville; Charles Mougenot; Bruno Quesson; Iulius Dragonu; Nicolas Grenier; Chrit T W Moonen
Journal:  Eur Radiol       Date:  2007-05-22       Impact factor: 5.315

5.  Fast temperature optimization of multi-source hyperthermia applicators with reduced-order modeling of 'virtual sources'.

Authors:  Kung-Shan Cheng; Vadim Stakhursky; Oana I Craciunescu; Paul Stauffer; Mark Dewhirst; Shiva K Das
Journal:  Phys Med Biol       Date:  2008-02-25       Impact factor: 3.609

6.  Fast PRF-based MR thermometry using double-echo EPI: in vivo comparison in a clinical hyperthermia setting.

Authors:  Tetiana Dadakova; Johanna Gellermann; Otilia Voigt; Jan Gerrit Korvink; John Matthew Pavlina; Jürgen Hennig; Michael Bock
Journal:  MAGMA       Date:  2014-11-08       Impact factor: 2.310

7.  Breath-hold MR-HIFU hyperthermia: phantom and in vivo feasibility.

Authors:  Chenchen Bing; Bingbing Cheng; Robert M Staruch; Joris Nofiele; Michelle Wodzak Staruch; Debra Szczepanski; Alan Farrow-Gillespie; Adeline Yang; Theodore W Laetsch; Rajiv Chopra
Journal:  Int J Hyperthermia       Date:  2019       Impact factor: 3.914

8.  Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia.

Authors:  G Bruggmoser; S Bauchowitz; R Canters; H Crezee; M Ehmann; J Gellermann; U Lamprecht; N Lomax; M B Messmer; O Ott; S Abdel-Rahman; M Schmidt; R Sauer; A Thomsen; R Wessalowski; G van Rhoon
Journal:  Strahlenther Onkol       Date:  2012-09       Impact factor: 3.621

9.  A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth.

Authors:  Gene L Bidwell; Eddie Perkins; Drazen Raucher
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

10.  Accurate temperature imaging based on intermolecular coherences in magnetic resonance.

Authors:  Gigi Galiana; Rosa T Branca; Elizabeth R Jenista; Warren S Warren
Journal:  Science       Date:  2008-10-17       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.